Leqvio® Cardiovascular, Renal and Metabolic Phase 3 ≥ 2027 siRNA (regulation of LDL-C) Secondary prevention of cardiovascular events in patients with elevated levels of LDLC (CVRR-LDLC) Supplementary Indication PrintPDF